Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer

Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma.

Immuno-oncology technology·2026

Trends in antidepressant use among children and adolescents: a Scandinavian drug utilization study.

Acta psychiatrica Scandinavica·2019

Drug response prediction in high-risk multiple myeloma.

Gene·2017

Societal costs of diabetes mellitus in Denmark.

Diabetic medicine : a journal of the British Diabetic Association·2015

Functional characterization of Foxp3-specific spontaneous immune responses.

Leukemia·2013

Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells.

Mitochondrion·2012

Research and development of a multi-target HER2 inhibitor (CPD 1) and its mechanism and application in combating HER2-positive breast cancer.

Cancer chemotherapy and pharmacology·2026

Antibody-drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges.

Cancer chemotherapy and pharmacology·2026

Pharmacological targeting of xCT/system Xc- to modulate temozolomide sensitivity in glioma and glioblastoma preclinical models: a focused systematic review.

Cancer chemotherapy and pharmacology·2026

Beyond gastric acid: pharmacologic modulation of the tumor microenvironment by vonoprazan and its drug-interaction implications for chemotherapy and immunotherapy.

Cancer chemotherapy and pharmacology·2026

Risk factors for immune-related adverse events associated with pembrolizumab in patients with solid tumors.

Cancer chemotherapy and pharmacology·2026

PROTACs in personalized and precision medicine: transforming targeted therapy with advances in selectivity and patient stratification.

Cancer chemotherapy and pharmacology·2026

Peri-interventional neutrophil extracellular traps and immune surveillance in hepatocellular carcinoma: mechanisms, biomarkers, and recurrence after liver resection or thermal ablation.

Frontiers in oncology·2026

Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.

Frontiers in medicine·2026

Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report.

Frontiers in immunology·2026

Lysosome-Bursting Calcium Carbonate Nanoparticles Amplify Immunogenic Cell Death via Synergistic Phototherapy and Calcium Overload for Immune Checkpoint Blockade.

Research (Washington, D.C.)·2026

Bio-based nanophotothermal systems as smart drug delivery platforms for multimodal synergistic cancer therapy-a review.

Frontiers in medical technology·2026

Stable disease after multimodal treatment of SMARCA4-deficient undifferentiated tumor concurrently involving the stomach and mediastinum: a case report.

Frontiers in oncology·2026

Related Experiment Videos

Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer

Related Concept Videos

Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma.

Trends in antidepressant use among children and adolescents: a Scandinavian drug utilization study.

Drug response prediction in high-risk multiple myeloma.

Societal costs of diabetes mellitus in Denmark.

Functional characterization of Foxp3-specific spontaneous immune responses.

Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells.

Research and development of a multi-target HER2 inhibitor (CPD 1) and its mechanism and application in combating HER2-positive breast cancer.

Antibody-drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges.

Pharmacological targeting of xCT/system Xc- to modulate temozolomide sensitivity in glioma and glioblastoma preclinical models: a focused systematic review.

Beyond gastric acid: pharmacologic modulation of the tumor microenvironment by vonoprazan and its drug-interaction implications for chemotherapy and immunotherapy.

Risk factors for immune-related adverse events associated with pembrolizumab in patients with solid tumors.

PROTACs in personalized and precision medicine: transforming targeted therapy with advances in selectivity and patient stratification.

Peri-interventional neutrophil extracellular traps and immune surveillance in hepatocellular carcinoma: mechanisms, biomarkers, and recurrence after liver resection or thermal ablation.

Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.

Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report.

Lysosome-Bursting Calcium Carbonate Nanoparticles Amplify Immunogenic Cell Death via Synergistic Phototherapy and Calcium Overload for Immune Checkpoint Blockade.

Bio-based nanophotothermal systems as smart drug delivery platforms for multimodal synergistic cancer therapy-a review.

Stable disease after multimodal treatment of SMARCA4-deficient undifferentiated tumor concurrently involving the stomach and mediastinum: a case report.

Related Experiment Videos

Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer

Related Concept Videos

Related Articles